June #188 : Generics Save Money but May Come With Risks - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


The Sound of Stigma

Artful Warriors

From the Editor

We Are Family


Letters-June 2013


Out of the Shadows

POZ Planet

Beyond the Pale

Koch vs. Koop

The New 'Normal'

Fountain of Youth

National HIV Coming Out Day?

To Be Continued

In the Beginning



Immigration Status

Care and Treatment

GMHC Treatment Issues June 2013

Generics Save Money but May Come With Risks

TasP Movement Gains Momentum

PIs in First Trimester Linked to Premature Births

Child 'Functionally Cured' of HIV?

Research Notes

Prevention: New Understanding of Old Vaccine

Treatment: CD4 Tests Needed Only Yearly?

Cure: Gene Therapy Has HIV in a Bind

Concerns: Health Threats Outside of AIDS

POZ Survey Says

The Doctor Is In

POZ Heroes


Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

June 2013

Generics Save Money but May Come With Risks

by Benjamin Ryan

As first-line HIV meds lose their patents, the U.S. health care system stands to save nearly $1 billion a year by switching to generic drugs, but switching may also lower the effectiveness of HIV therapy, according to a study conducted by Massachusetts General Hospital and Weill Cornell Medical College.

Atripla, which is a combination of three brand name drugs—Viread (tenofovir), Emtriva (emtricitabine) and Sustiva (efavirenz)—faces generic competition: A generic form of the antiretroviral lamivudine, which is similar to emtricitabine, was released in 2012, and a generic equivalent of efavirenz is expected soon.

The study projects that using the two generics with Viread would achieve an average lifetime savings of $42,500 over Atripla. However, the increased pill burden—the generic meds would not come in a single, combo tablet—would raise the likelihood of low medication adherence, which can lead to treatment failure. Also, some studies have suggested lamivudine may be somewhat less effective than emtricitabine, as well as more likely to lead to drug resistance.

“Ideally, what we would try to do is identify sub-groups of patients where that substitution would not have adverse effects,” says the study’s senior author, Bruce R. Schackman, PhD, an associate professor of public health at Cornell.

Search: generics, drug patents, Atripla, Viread, Emtriva, Sustiva, adherence, drug resistance

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.